Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has issued an announcement.
Q-linea has secured U.S. FDA 510(k) clearance for an expanded Gram-negative blood culture testing menu on its ASTar platform, significantly broadening the system’s clinical scope. The updated Version 2 panel now offers 215 bug–drug combinations, about 75% more than the earlier version, and incorporates key antibiotics such as Ceftriaxone, Cefotaxime, Ceftolozane-tazobactam and Ertapenem.
The new panel also introduces upgraded performance algorithms and aligns with the latest FDA breakpoints, positioning ASTar as one of the most up-to-date phenotypic susceptibility solutions for U.S. laboratories and clinicians. By more closely matching the CE-IVDR-cleared European offering, the clearance strengthens Q-linea’s competitive footing in the U.S. market and is expected to support better sepsis care, faster optimization of targeted antibiotic therapy and potential cost savings for healthcare systems.
More about Q-linea AB
Q-linea AB is a Swedish infection diagnostics company focused on rapid antibiotic susceptibility testing (rAST) to support treatment of sepsis and other severe infections. Its flagship product, the fully automated ASTar platform, delivers rapid phenotypic results from positive blood cultures in about six hours, helping clinicians optimize antibiotic use and combat antimicrobial resistance.
YTD Price Performance: -12.99%
Average Trading Volume: 9,773
Technical Sentiment Signal: Sell
Current Market Cap: SEK404.1M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.